Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson’s disease in the MPTP-induced mice model

References

• Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y. (2001). Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci, 12, 231–238.
   PubMed Web of Science ®Google Scholar
• Black KJ, Carl JL, Hartlein JM, Warren SL, Hershey T, Perlmutter JS. (2003). Rapid intravenous loading of levodopa for human research: Clinical results. J Neurosci Methods, 127, 19–29.
   PubMed Web of Science ®Google Scholar
• Bigotte L. (1985). Doxorubicin as a fluorescent nuclear marker in tumors of the human nervous system: A simple and reliable staining technique. Clin Neuropathol, 4, 220–226.
   PubMed Web of Science ®Google Scholar
• Dai W, Yang T, Wang X, Wang J, Zhang X, Zhang Q. (2010). PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells. J Drug Target, 18, 254–263.
   PubMed Web of Science ®Google Scholar
• Dai X, Yue Z, Eccleston ME, Swartling J, Slater NK, Kaminski CF. (2008). Fluorescence intensity and lifetime imaging of free and micellar-encapsulated doxorubicin in living cells. Nanomedicine, 4, 49–56.
   PubMed Web of Science ®Google Scholar
• DeBin JA, Strichartz GR. (1991). Chloride channel inhibition by the venom of the scorpion Leiurus quinquestriatus. Toxicon, 29, 1403–1408.
   PubMed Web of Science ®Google Scholar
• de Boer AG, Gaillard PJ. (2007). Drug targeting to the brain. Annu Rev Pharmacol Toxicol, 47, 323–355.
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Carafa M, Sozio P, Pinnen F, Braghiroli D, Orlando G, Cannazza G, Ricciutelli M, Marianecci C, Santucci E. (2004). Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations. J Control Release, 99, 293–300.
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Sozio P, Iannitelli A, Marianecci C, Santucci E, Carafa M. (2006). Maleic- and fumaric-diamides of (O,O-diacetyl)-L-dopa-methylester as anti-Parkinson prodrugs in liposomal formulation. J Drug Target, 14, 652–661.
   PubMed Web of Science ®Google Scholar
• Düzgüne&scedil N, Nir S. (1999). Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev, 40, 3–18.
   Google Scholar
• Fahn S, Przedborski S. (2005). Parkinsonism. In: Rowland LP, ed. Merritt’s Neurology, 10th ed. Philadelphia: Lippincott Williams & Wilkins, pp. 828–846.
   Google Scholar
• Fahn S. (2006). Levodopa in the treatment of Parkinson’s disease. J Neural Transm Suppl, 71, 1–15.
   Google Scholar
• Goole J, Amighi K. (2009). Levodopa delivery systems for the treatment of Parkinson’s disease: An overview. Int J Pharm, 380, 1–15.
   PubMed Web of Science ®Google Scholar
• Haran G, Cohen R, Bar LK, Barenholz Y. (1993). Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta, 1151, 201–215.
   PubMed Web of Science ®Google Scholar
• Jacoby DB, Dyskin E, Yalcin M, Kesavan K, Dahlberg W, Ratliff J, Johnson EW, Mousa SA. (2010). Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide. Anticancer Res, 30, 39–46.
   PubMed Web of Science ®Google Scholar
• Jankovic J. (2002). Levodopa strengths and weaknesses. Neurology, 58, S19–S32.
   PubMed Web of Science ®Google Scholar
• Kachra Z, Beaulieu E, Delbecchi L, Mousseau N, Berthelet F, Moumdjian R, Del Maestro R, Béliveau R. (1999). Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis, 17, 555–566.
   PubMed Web of Science ®Google Scholar
• Kesavan K, Ratliff J, Johnson EW, Dahlberg W, Asara JM, Misra P, Frangioni JV, Jacoby DB. (2010). Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects. J Biol Chem, 285, 4366–4374.
   PubMed Web of Science ®Google Scholar
• Kopin IJ, Markey SP. (1988). MPTP toxicity: Implications for research in Parkinson’s disease. Annu Rev Neurosci, 11, 81–96.
   PubMed Web of Science ®Google Scholar
• Lach B, Grimes D, Benoit B, Minkiewicz-Janda A. (1992). Caudate nucleus pathology in Parkinson’s disease: Ultrastructural and biochemical findings in biopsy material. Acta Neuropathol, 83, 352–360.
   PubMed Web of Science ®Google Scholar
• Leng A, Mura A, Hengerer B, Feldon J, Ferger B. (2004). Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice. Behav Brain Res, 154, 375–383.
   PubMed Web of Science ®Google Scholar
• Lou J, Gasche Y, Zheng L, Critico B, Monso-Hinard C, Juillard P, Morel P, Buurman WA, Grau GE. (1998). Differential reactivity of brain microvascular endothelial cells to TNF reflects the genetic susceptibility to cerebral malaria. Eur J Immunol, 28, 3989–4000.
   PubMed Web of Science ®Google Scholar
• Lyons SA, O’Neal J, Sontheimer H. (2002). Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia, 39, 162–173.
   PubMed Web of Science ®Google Scholar
• Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, Levey AI. (1997). Immunochemical analysis of dopamine transporter protein in Parkinson’s disease. Ann Neurol, 41, 530–539.
   PubMed Web of Science ®Google Scholar
• Nagatsu T, Sawada M. (2009). L-dopa therapy for Parkinson’s disease: Past, present, and future. Parkinsonism Relat Disord, 15 (Suppl. 1), S3–S8.
   PubMed Web of Science ®Google Scholar
• Nowacek A, Kosloski LM, Gendelman HE. (2009). Neurodegenerative disorders and nanoformulated drug development. Nanomedicine (Lond), 4, 541–555.
   PubMed Web of Science ®Google Scholar
• Oertel WH, Ellgring H. (1995). Parkinson’s disease–medical education and psychosocial aspects. Patient Educ Couns, 26, 71–79.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2002). Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov, 1, 131–139.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2007a). Blood-brain barrier delivery. Drug Discov Today, 12, 54–61.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. (2007b). Drug targeting to the brain. Pharm Res, 24, 1733–1744.
   PubMed Web of Science ®Google Scholar
• Rozas G, López-Martín E, Guerra MJ, Labandeira-García JL. (1998). The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods, 83, 165–175.
   PubMed Web of Science ®Google Scholar
• Samad A, Sultana Y, Aqil M. (2007). Liposomal drug delivery systems: An update review. Curr Drug Deliv, 4, 297–305.
   PubMedGoogle Scholar
• Schmidt N, Ferger B. (2001). Neurochemical findings in the MPTP model of Parkinson’s disease. J Neural Transm, 108, 1263–1282.
   PubMed Web of Science ®Google Scholar
• Shastry BS. (2001). Parkinson disease: Etiology, pathogenesis and future of gene therapy. Neurosci Res, 41, 5–12.
   PubMed Web of Science ®Google Scholar
• Sommer B, Barbieri S, Hofele K, Wiederhold K, Probst A, Mistl C, Danner S, Kauffmann S, Spooren W, Tolnay M, Bilbe G, van der Putten H, Kafmann S, Caromi P, Ruegg MA. (2000). Mouse models of alpha-synucleinopathy and Lewy pathology. Exp Gerontol, 35, 1389–1403.
   PubMed Web of Science ®Google Scholar
• Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, Ravanpay AC, Stroud MR, Kusuma Y, Hansen SJ, Kwok D, Munoz NM, Sze RW, Grady WM, Greenberg NM, Ellenbogen RG, Olson JM. (2007). Tumor paint: A chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res, 67, 6882–6888.
   PubMed Web of Science ®Google Scholar
• Veiseh O, Sun C, Fang C, Bhattarai N, Gunn J, Kievit F, Du K, Pullar B, Lee D, Ellenbogen RG, Olson J, Zhang M. (2009). Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res, 69, 6200–6207.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Muramatsu Y, Kurosaki R, Michimata M, Matsubara M, Imai Y, Araki T. (2004). Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: An immunohistological study. Eur Neuropsychopharmacol, 14, 93–104.
   PubMed Web of Science ®Google Scholar
• Xiong XB, Huang Y, Lu WL, Zhang H, Zhang X, Zhang Q. (2005). Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res, 22, 933–939.
   PubMed Web of Science ®Google Scholar
• Xu YG, Pang XF, Gi JJ. (2006). The evaluation and method on several typical MPTP-induced mouse PD models. Prog Biochem Biophys, 33, 1014–1018.
   Google Scholar
• Yang ZD, Zhang X, Guo H, Gan Y. (2006). Simultaneous determination of monoamines, their precursor amino acids and related metabolites in mice brain by high-performance liquid chromatography with a coulometric electrode array system. Anal Lett, 39, 1837–1851.
   Web of Science ®Google Scholar
• Zhang J, Jin W, Wang X, Wang J, Zhang X, Zhang Q. (2010). A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharm, 7, 1159–1168.
   PubMed Web of Science ®Google Scholar